30 results about "Urinary excretion" patented technology

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides / radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides / radiometals or paramagnetic ions may be conjugated to the nanoparticle.

The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and / or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.

The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and / or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.

An extra-labia urine voiding apparatus including a container sized and shaped to externally cover a vulval region of a female anatomy. The container has an open side and defines a reservoir that is adapted for receiving urine. The container also includes a substantially planar surface disposed at a top of the container adapted to face and generally surround a periphery of the vulval region. An extra-labia sealing structure is affixed to the planar surface of the top of the container. The sealing structure includes a pressure sensitive adhesive adapted to provide a generally fluid tight primary adhesive seal between the container and external tissue generally surrounding the vulval region. A blocking mechanism connected proximate the top of the container prevents escape of urine from the voiding apparatus and contact of urine with the vulval region of the female anatomy. The voiding apparatus also includes a conduit in fluid communication with the reservoir of the container and adapted for draining urine from the reservoir.

The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and / or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered waste nitrogen scavenging drug, and to monitoring patients receiving such drugs.

A method of screening a candidate compound for susceptibility to biliary excretion. The method includes the steps of providing a culture of hepatocytes, the culture having at least one bile canaliculus; exposing a candidate compound to the culture; and determining an amount of candidate compound in the at least one bile canaliculus, the amount of candidate compound in the at least one bile canaliculus indicating the susceptibility of the candidate compound to biliary excretion. Optionally, the culture of hepatocytes is a long-term culture in a sandwich configuration. The method is particularly applicable to the screening of multiple candidate compounds in a single effort.

An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect.The present invention provides a compound represented by the general formula (I):(wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and / or improving symptoms thereof, containing them as an active ingredient.

A daily urinary excretion measurement apparatus and a method thereof, for measuring daily excretion of a urine component highly accurately and easily, are provided.A daily urinary excretion measurement apparatus (100) includes: a urine component calculation unit (411) which measures the amount of the urine component included in before-bedtime urine that is excreted for the last time before bedtime in the day and the amount (salt) of the urine component (salt) included in overnight urine that is excreted for the first time after wake-up on the next day following a sleep; a regression equation storage unit (416) which stores a correlation (a regression equation) between the amount of the before-bedtime urine component and the amount of the overnight urine component and a total amount of the urine component included in daily urine; a daily urinary excretion calculation unit (413) which calculates the total amount of the urine component excreted in the daily urine according to the regression equation stored in the regression equation storage unit (416), using the amount of the before-bedtime urine component (salt) and the amount of the overnight urine component (salt) calculated by the urine component calculation unit (411).

The invention discloses a plant composition for treating hyperuricemia and gout and plant composition solid granules. The plant composition is prepared from celery seed extract, corn silk powder, pumpkin powder, lotus leaf powder, mulberry powder, ginseng powder grape powder by mixing. The plant composition solid granules are mainly prepared from the plant composition. According to the plant composition for treating the hyperuricemia and the gout and the plant composition solid granules, the celery seed extract, the corn silk powder, the pumpkin powder, the lotus leaf powder, the mulberry powder, the ginseng powder and the grape powder are compounded for use to improve the nutritional compositions, and the celery seed extract can significantly reduce the serum uric acid level and the urineuric acid level of the hyperuricemia; the corn silk powder and the lotus leaf powder can accelerate urinary excretion and help uric acid excretion; and the pumpkin powder, the mulberry powder, the ginseng powder and the grape powder have the functions of nourishing the liver and kidney, enhancing immunity and protecting the liver and kidney. The action mechanism of each component is different, multi-component mixing effectively exerts the synergistic effect between the components, the action time is prolonged, the curative effect is enhanced, and the components are homologous to medicine andfood, are safe and have no side effects.

An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect.The present invention provides a compound represented by the general formula (I):(wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and / or improving symptoms thereof, containing them as an active ingredient.

This invention provides a waste issue alarm device to detect and indicate the weight increment of new urine issue or feces issue in the diaper, and transmit a waste issue alarm. The number of the urine or feces issue is counted separately. The waste issue alarm will indicate the count of the urine issue and the feces issue and their weights. An adjustable belt unit with hanger is used to hold the waste issue alarm device and hang it outside the diaper. A remote alarm may also be used. It may also monitor the urine issue and the feces issue of multiple diapers. An emergency alarm may be activated when the carried component of the device is submerged in the water.

The invention discloses a medicine composition resisting gout, promoting renal excretion, and repairing renal injury, as well as a preparation method and an application for the same. The composition is prepared from the following components in parts by weight: 1-5 parts by weight of polygonum cuspidatum, 1-5 parts by weight of turmeric, 1-5 parts by weight of salviae miltiorrhizae, and 1-5 parts by weight of panax japonicus. The medicine composition can be prepared via an alcohol extraction method or a water extraction method. The medicine composition aforementioned has the remarkable effects of resisting gout, repairing renal injury, and increasing renal excretion amount.

The invention discloses a traditional Chinese medicinal preparation for treating urinary system infection, wherein the traditional Chinese medicinal preparation consists of radix sophorae flavescentis, corn stigma, herba portulacae, herba pyrrosiae, fructus forsythiae, radix bupleuri, lalang grass rhizome, pericarpium granati, shrubalthea flower, medicated leaven, eucommia bark, herba leonuri, humifuse euphorbia herb, herba dianthi, talcum, radix et rhizoma rhei and fructus toosendan; the traditional Chinese medicinal preparation disclosed by the invention has good functions of giving consideration to both deficiency and excess on inhibiting bacteria and relieving swelling, relieving pain and promoting diuresis, enhancing immunity, tonifying deficiency and benefiting kidney, promoting blood circulation and removing stasis, and the like; the traditional Chinese medicinal preparation is researched on the basis of the etiology and pathology of stranguria; the traditional Chinese medicinal preparation disclosed by the invention is mild in nature, and the traditional Chinese medicinal preparation not only can enrich blood but also can stop bleeding; the traditional Chinese medicinal preparation, which is relatively strong in diuresis promoting effect, can promote the excretion of residual antibiotics in a body along with urine through kidney; the traditional Chinese medicinal preparation is also relatively strong in antibacterial effect on pathogenic bacteria of urinary tract, and the traditional Chinese medicinal preparation is beneficial for the discharge of the pathogenic bacteria and toxins thereof out of the body under the flushing of the urine; and in addition, the traditional Chinese medicinal preparation is capable of promoting blood circulation in inflammatory parts, repairing tissue structures of diseased parts, regulating overall functions, and improving and enhancing the resistance capacity of the body; therefore, the traditional Chinese medicinal preparation is an ideal traditional Chinese medicinal preparation for treating the urinary system infection.

The presented invention describes a noninvasive urinary aid for persons with vaginas. Which allows persons with vaginas to urinate without leaking, disrobing, or wiping, in a standing position. The urinary aids are manufactured of a pliable silicone and may be used repeatedly. When in use, the inlet opening is placed between the labia, pressed around the urethral opening to form a leak proof seal which creates a passage for urine excretion beyond the wearer's clothing. This ensures all urine is guided, via the urethral cup and connected tubing, to the location desired for disposal. The vulva, upon completion of urination, will not need to be dried.I hereby state that the submission, filed in accordance with 37 CFR 1.821(g), herein does not include new matter which goes beyond the initial disclosures in the international application.

Disclosed is an EP1 antagonist, particularly a compound represented by the formula (I):wherein all symbols are as defined in the description,a salt thereof, a solvate thereof or a prodrug thereof. The compound, a salt thereof, a solvate thereof or a prodrug thereof is effective for prevention, treatment and / or symptom improvement of a dysuria (e.g., slow stream, splitting or spraying of the urine stream, intermittent stream, hesitancy, straining to void or terminal dribble).

An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect.The present invention provides a compound represented by the general formula (I):(wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and / or improving symptoms thereof, containing them as an active ingredient.

The invention relates to the technical field of bathroom products. The invention discloses a closestool with a male urine channel. The closestool comprises a closestool body, a water tank, a closestool edge and a rotating shaft, a fixing base is installed on the portion, located on the left side of the rotating shaft, of the top of the closestool body, a telescopic guide groove is formed in the portion, located in an inner cavity of the closestool body, of the right side of the fixing base, and a urinal is arranged at the end, away from the fixing base, of the telescopic guide groove. The invention discloses the closestool with the male urine channel, the urine channel is arranged, when the closestool is used by a man, the upwarp of the urine channel can be realized only by pressing down abutton; when the man urinates, the urine can enter the closestool body through the telescopic guide groove and a urination groove as long as the urine is excreted into the urinal; by means of the arrangement, it can be guaranteed that urine enters the closestool body along the telescopic guide groove, on one hand, the cleanness and sanitation of the edge of the closestool are guaranteed, and on the other hand, it can also be guaranteed that a toilet has no unpleasant smell without frequently cleaning the edge of the closestool.

This document provides methods and materials involved in assessing intestinal permeability of a mammal. For example, methods and materials for administering 13C-mannitol to a mammal (e.g., a human) and determining urinary excretion of 13C-mannitol as a measure of intestinal permeability of a mammal are provided.

The invention discloses a method for deriving exposure characteristics of compounds in plasma from urine excretion data, which comprises the following steps of: under the condition of single-dose or multi-dose intravenous injection (including infusion) or oral administration, fitting a two-atrioventricular distribution model or a three-atrioventricular distribution model aiming at a urine excretion curve by utilizing a semi-logarithmic end linear regression method; and calculating the urine clearance rate CLr by adopting single-point plasma drug concentration data to correct and finally acquire a plasma drug concentration-time curve. According to the method, urine excretion data and single-point plasma drug concentration data are obtained through non-invasive sampling, a plasma exposure curve is fitted and reversely deduced through a mathematical means, and the bottleneck problem that blood sampling is difficult in pharmacokinetic research of special crowds is solved.